GERN - Geron Corporation
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs FOSTER CITY, Calif.
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million Company to host conference call and webcast today, May 6, 2026, at 8:00 a.m.
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: Bank of America Securities 2026 Healthcare Conference Presentation on Tuesday, May 12 at 4:35 p.m.
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Geron (NASDAQ: GERN) executives used a presentation at the Needham Healthcare Conference to outline the company's early commercial trajectory for its telomerase inhibitor imetelstat (marketed as RYTELO) in lower-risk myelodysplastic syndromes (MDS), provide updated views on physician adoption dynamics, and discuss the ongoing Phase 3 myelofibrosis (MF) program. Commercial launch status and financial outlook President and
FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 2,500,000 shares of Geron common stock to Timothy Williams, Geron's new Executive Vice President, Chief Legal Officer and Corporate Secretary, as an inducement material to his acceptance of employment with Geron.
Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET.
Geron Corporation (NASDAQ: GERN - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.38 and traded as high as $1.43. Geron shares last traded at $1.41, with a volume of 16,679,509 shares. Analyst Ratings Changes Several brokerages recently issued reports
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies
Shares of Geron Corporation (NASDAQ: GERN - Get Free Report) have been assigned an average rating of "Hold" from the seven analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company.
Geron Corporation's Q4 '25 net product revenues of $48M are similar to those seen in Q4 '24 ($47.5M). Despite fairly flat quarterly revenues, GERN maintains 2026 net product revenue guidance of $220M-$240M, implying 25% growth. Key catalysts include a potential IMpactMF interim readout in H2 '26 and readouts from investigator-sponsored trials and potential real-world data that could encourage use of Rytelo.
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase an aggregate of 956,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.